Promoting the development and commercialization of innovative new drugs in the field of neurological and psychiatric diseases; in-licensing, development, and marketing of unapproved drugs in Japan that have been launched in the U.S. andEurope      

Actively utilizing digital technology and partnerships to provide solutions to various issues surrounding diseases; specifically, conducting clinical trials using blockchain technology, and collecting and utilizing real-world data from treatment apps, wearable devices, etc.